Last reviewed · How we verify
SAR245408
At a glance
| Generic name | SAR245408 |
|---|---|
| Sponsor | Sanofi |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Open Label Treatment Extension Study With SAR245408 or SAR245409 as a Monotherapy or as a Combination Regimen (PHASE1, PHASE2)
- Study of XL147 (SAR245408) in Advanced or Recurrent Endometrial Carcinoma (PHASE2)
- Study of XL147 (SAR245408) in Combination With Trastuzumab or Paclitaxel and Trastuzumab in Subjects With Metastatic Breast Cancer Who Have Progressed on a Previous Trastuzumab-based Regimen (PHASE1, PHASE2)
- Study of XL147 (SAR245408) or XL765 (SAR245409) in Combination With Letrozole in Subjects With Breast Cancer (PHASE1, PHASE2)
- A Study of the Safety and Pharmacokinetics of SAR245408 Tablets in Patients With Solid Tumors or Lymphoma (PHASE1)
- Oral SAR245408 (XL147) and Oral MSC1936369B in Patients With Locally Advanced or Metastatic Solid Tumors (PHASE1)
- Safety Study of XL647 and XL147 Administered in Combination Daily in Adults With Solid Tumors (PHASE1)
- Safety and Pharmacokinetics of SAR245408 Daily Oral in Patients With Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SAR245408 CI brief — competitive landscape report
- SAR245408 updates RSS · CI watch RSS
- Sanofi portfolio CI